Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction

被引:48
作者
Vanderheyden, M.
Bartunek
Claeys, G.
Manoharan, G.
Beckers, J. F.
Ide, L.
机构
[1] Onze Lieve Vrouw Hosp, Ctr Cardiovasc, B-9400 Aalst, Belgium
[2] Univ Ziekenhuis Gasthuisberg, Lab Med Clin Chem, B-3000 Louvain, Belgium
[3] Onze Lieve Vrouw Hosp, Biochem Lab, B-9400 Aalst, Belgium
关键词
B-type natriuretic peptides; heart failure; cardiac markers;
D O I
10.1016/j.clinbiochem.2006.01.021
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Human pro-B-type natriuretic peptide is cleaved into the active B-type natriuretic peptide (BNP) and the inactive fragment NT-proBNP. It is unclear if, similar to BNP, NT-proBNP can be used as a marker of impaired left ventricular (LV) ejection fraction (EF). This study evaluated the analytical performance of both assays to detect LV systolic dysfunction. Methods: In 72 patients with various degrees of left ventricular systolic dysfunction (LVSD), blood analysis for BNP and NT-proBNP was performed prior to cardiac catheterization, using a point-of-care analyzer (Biosite) and a fully automated laboratory analyzer (Roche-Elecsys), respectively. The within-run and between-run imprecision for BNP and NT-proBNP was calculated. Results: Both markers were able to detect impaired LV EF with the largest area under the receiver-operating-characteristic curve for NT-proBNP (NT-proBNP: 0.851 (0.747-0.924); BNP: 0.803 (0.692-0.887) 95% confidence interval; P = 0.07). A significant correlation was observed between BNP and NT-proBNP (r 0.9; P < 0.0001). Estimating the within-run imprecision, the coefficient of variance for BNP was 3.14% (n = 20, mean 316 ng/L) to 3.32% (n 20, mean 820 ng/L) and for NT-proBNP 0.9% (n = 20, mean 4390.8 ng/L) to 1.4% (n = 20, mean 225 ng/L). The between-run imprecision for NT-proBNP ranged between 2.1% (n = 20, mean 224.6 ng/L) and 2% (n = 20, mean 4391 ng/L). Optimal discriminator values for BNP and NT-proBNP were 139 ng/L and 358 ng/L, respectively. However, adjusting the BNP cut-off value to 54 ng/L improved the negative predictive value and sensitivity of the assay. Conclusion: Similar to BNP, NT-proBNP is a promising marker in identifying LVSD. Although both assays are reliable and have good analytical performance, their diagnostic cut-off value is dynamic and population-dependent. The slightly wider detection range and the more stable structure of NT-proBNP compared to the BNP assay suggest that NT-proBNP could play an additional role in the evaluation of patients with LV systolic dysfunction. (c) 2006 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:640 / 645
页数:6
相关论文
共 23 条
[1]   Analytical correlation between plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in patients presenting with dyspnea [J].
Alibay, Y ;
Beauchet, A ;
El Mahmoud, R ;
Brun-Ney, D ;
Alexandre, JA ;
Benoit, MO ;
Dubourg, O ;
Aegerter, P ;
Boileau, C ;
Jondeau, G ;
Puy, H .
CLINICAL BIOCHEMISTRY, 2004, 37 (10) :933-936
[2]   Diastolic heart failure [J].
Maurer, MS ;
Packer, M ;
Burkhoff, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (11) :1143-1143
[3]   A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study [J].
Cheng, V ;
Kazanagra, R ;
Garcia, A ;
Lenert, L ;
Krishnaswamy, P ;
Gardetto, N ;
Clopton, P ;
Maisel, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :386-391
[4]   Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review [J].
Clerico, A ;
Emdin, M .
CLINICAL CHEMISTRY, 2004, 50 (01) :33-50
[5]   B-type natriuretic peptide in cardiovascular disease [J].
de Lemos, JA ;
McGuire, DK ;
Drazner, MH .
LANCET, 2003, 362 (9380) :316-322
[6]  
De Meester I, 2003, ADV EXP MED BIOL, V524, P3
[7]   Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment [J].
Hunt, PJ ;
Richards, AM ;
Nicholls, MG ;
Yandle, TG ;
Doughty, RN ;
Espiner, EA .
CLINICAL ENDOCRINOLOGY, 1997, 47 (03) :287-296
[8]   ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the evaluation and management of heart failure) [J].
Hunt, SA ;
Baker, DW ;
Chin, MH ;
Cinquegrani, MP ;
Feldman, AM ;
Francis, GS ;
Ganiats, TG ;
Goldstein, S ;
Gregoratos, G ;
Jessup, ML ;
Noble, RJ ;
Packer, M ;
Silver, MA ;
Stevenson, LW ;
Gibbons, RJ ;
Antman, EM ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Jacobs, AK ;
Hiratzka, LF ;
Russell, RO ;
Smith, SC .
CIRCULATION, 2001, 104 (24) :2996-3007
[9]   Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV [J].
Lambeir, AM ;
Durinx, C ;
Scharpé, S ;
De Meester, I .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2003, 40 (03) :209-+
[10]   Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction - Results from the breathing not properly multinational study [J].
Maisel, AS ;
McCord, J ;
Nowak, RM ;
Hollander, JE ;
Wu, AHB ;
Duc, P ;
Omland, T ;
Storrow, AB ;
Krishnaswamy, P ;
Abraham, WT ;
Clopton, P ;
Steg, G ;
Aumont, MC ;
Westheim, A ;
Knudsen, CW ;
Perez, A ;
Kamin, R ;
Kazanegra, R ;
Herrmann, HC ;
McCullough, PA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (11) :2010-2017